Endocrinology. What changed.

New drugs and devices in endocrinology, newest first, each with its bottom line.

As of Aug 25, 2026, Clintelo tracks 2 innovations in endocrinology: 1 drug (Foundayo (orforglipron)) and 1 device (Libre Duo). Each is written from the FDA's announcement or the developer's own release.

Drug IQ in Endocrinology

Search 1 in Drug IQ

Drug IQFDA approvalApr 1, 2026Foundayo (orforglipron)Chronic weight management · Eli LillyAdults who qualify for weight management therapy have a GLP-1 receptor agonist option taken as a daily tablet. It should not be combined with another GLP-1 receptor agonist.

Device IQ in Endocrinology

Search 1 in Device IQ

Device IQGranted · De NovoAug 25, 2026Libre DuoDiabetes: continuous ketone and glucose monitoring · AbbottPatients with diabetes can now see ketone and glucose levels and trends together in real time from one device, with alerts that may help them and their caregivers recognize rising ketones before diabetic ketoacidosis becomes an emergency. The FDA notes that ketone information should always be interpreted in the context of glucose readings and symptoms.